Antioxidant therapy attenuates oxidative insult caused by benzonidazole in chronic Chagas` heart disease


Autoria(s): RIBEIRO, Carine Muniz; BUDNI, Patricia; PEDROSA, Roberto Coury; FARIAS, Mirelle Sifroni; PARISOTTO, Eduardo Benedetti; DALMARCO, Eduardo Monguilhott; FROEDE, Tania Silva; OLIVEIRA-SILVA, Diogo; COLEPICOLO, Pio; WILHELM FILHO, Danilo
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2010

Resumo

Chronic chagasic cardiac patients are exposed to oxidative stress that apparently contributes to disease progression. Benznidazole (BZN) is the main drug used for the treatment of chagasic patients and its action involves the generation of reactive species. 41 patients with Chagas` heart disease were selected and biomarkers of oxidative stress were measured before and after 2 months of BZN treatment (5 mg/kg/day) and the subsequent antioxidant supplementation with vitamin E (800 UI/day) and C (500 mg/day) during 6 months. Patients were classified according to the modified Los Andes clinical hemodynamic classification in groups IA, IB, II and III, and the activity of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione S-transferase (GST) and glutathione reductase (GR), as well as the contents of reduced glutathione (GSH), thiobarbituric acid reactive species (TBARS), protein carbonyl (PC), vitamin E and C and nitric oxide (NO), myeloperoxidase (MPO) and adenosine deaminase (ADA) activities were measured in their blood. Excepting in group III, after BZN treatment SOD, CAT, GPx and GST activities as well as PC levels were enhanced while vitamin E levels were decreased in these groups. After antioxidant supplementation the activities of SOD, GPx and GR were decreased whereas PC, TBARS, NO, and GSH levels were decreased. In conclusion, BZN treatment promoted an oxidative insult in such patients while the antioxidant supplementation was able to attenuate this effect by increasing vitamin E levels, decreasing PC and TBARS levels, inhibiting SOD, GPx and GR activities as well as inflammatory markers, mainly in stages with less cardiac involvement. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)/MCT/Ministério da Saúde MS-SCTIE-DECIT

CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)/MCT/Ministério da Saúde MS-SCTIE-DECIT[409266/2006-0]

CNPq[305018/2006-0]

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

PIBIC-CNPq

Identificador

INTERNATIONAL JOURNAL OF CARDIOLOGY, v.145, n.1, p.27-33, 2010

0167-5273

http://producao.usp.br/handle/BDPI/30952

10.1016/j.ijcard.2009.06.033

http://dx.doi.org/10.1016/j.ijcard.2009.06.033

Idioma(s)

eng

Publicador

ELSEVIER IRELAND LTD

Relação

International Journal of Cardiology

Direitos

restrictedAccess

Copyright ELSEVIER IRELAND LTD

Palavras-Chave #Chagas` disease #Cardiopathy #Benzonidazole #Oxidative stress #Antioxidant supplementation #Vitamin E #VITAMIN-E #TRYPANOSOMA-CRUZI #SUPEROXIDE-DISMUTASE #ETIOLOGIC TREATMENT #HYDROGEN-PEROXIDE #RED-CELLS #BENZNIDAZOLE #GLUTATHIONE #OXYGEN #STRESS #Cardiac & Cardiovascular Systems
Tipo

article

original article

publishedVersion